ERS 2024 - Effects of angiotensin II type 2 receptor agonist buloxibutid on human lung myofibroblasts and human IPF lung tissue
Download picture
ERS 2024 - AIR – an open-label, 36-week, clinical trial of buloxibutid – investigating the disease modifying potential of a novel angiotensin II type 2 receptor agonist in IPF
Download picture
ERS 2024 - Patients and caregivers’ core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF
Download picture
ERS 2024 - COMPANION - a randomized controlled study to evaluate the impact of a digital therapy on anxiety and quality of life in patients with pulmonary fibrosis
Download picture
ARLDSC 2024 - Patients and caregivers’ core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF
Download picture
ATS 2024 - Buloxibutid (C21), a Novel Angiotensin II Type 2 Receptor Agonist in the 36-week Phase 2a AIR Trial Stabilized and Improved Lung Function in Individuals with Idiopathic Pulmonary Fibrosis (IPF)
Download picture
ATS 2024 - ASPIRE – crafting a patient-focused 52 week phase 2b trial of buloxibutid (C21), an oral angiotensin II type 2 receptor agonist, in patients with IPF
Download picture
ATS 2024 - Deciphering the clinical efficacy mechanisms of buloxibutid (C21) in idiopathic pulmonary fibrosis
Download picture
RIS at ATS 2024 - We have a vision to stop disease progression and restore function - That’s why we are unlocking the potential of a new class of drugs
Download picture
EU-PF Summit 2024 -A digital therapy to address the anxiety associated with pulmonary fibrosis
Download picture
EU-PF Summit 2024 - ASPIRE - Involving patients and caregivers when designing a trial to evaluate the efficacy and safety of buloxibutid
Download picture
PFF Summit 2023- Interim Analysis of AIR - An Open-label, Single Arm, 36-week Phase 2a Trial of the Angiotensin II Type 2 Receptor Agonist (ATRAG), C21, in Individuals with IPF
Download picture
PFF Summit 2023 - ASPIRE – a patient friendly trial evaluating whether C21 improves lung function in IPF
Download picture
PFF Summit 2023 - A personalized treatment for anxiety and challenges of living with Pulmonary Fibrosis
Download picture
ERS 2023 - Characterization of high responders in the phase 2a IPF AIR trial of C21 using baseline quantitative CT image analysis
Download picture
ERS 2023 - An open label, pharmacodynamic trial investigating vascular effects of the angiotensin II type 2 receptor agonist (ATRAG) C21
Download picture
ATS 2023 - Development of angiotensin II type 2 receptor agonists (ATRAGs) for treatment of pulmonary fibrosis and pulmonary hypertension
Download picture
ATS 2023 - A digital therapeutic for anxiety symptoms in patients with IPF
Download picture
ATS/RIS 2023 - Vicore - we have a vision to stop disease progression and restore function - that’s why we are unlocking the potential of a new class of drugs
Download picture